Global Vaccin Antirabic Market Research Report 2022

Rabies vaccine is a vaccine to prevent the occurrence of rabies.The vaccine is very good at preventing wound infection.It can be divided into two types: one is post-exposure (bite, scratch) prevention, and the other is pre-exposure (no bite, scratch) prevention.
Due to the COVID-19 pandemic, the global Vaccin Antirabic market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Vaccin Antirabic market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Vaccin Antirabic landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Gopher Kidney Cell Vaccine accounting for % of the Vaccin Antirabic global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Pre-exposure Prophylaxis segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Vaccin Antirabic include GSK, Sanofi, Chengda, Yisheng, Merck, VACN, Changsheng, BCHT and Hissen, etc. In terms of revenue, the global 3 largest players have a % market share of Vaccin Antirabic in 2021.
This report focuses on Vaccin Antirabic volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Vaccin Antirabic market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Vaccin Antirabic Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Gopher Kidney Cell Vaccine
Freeze-Dried Vero Cell Vaccine
Common Vero Cell Vaccines
Human Diploid Vaccine
Segment by Application
Pre-exposure Prophylaxis
After Exposure Prophylaxis
Additional Doses
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
GSK
Sanofi
Chengda
Yisheng
Merck
VACN
Changsheng
BCHT
Hissen
Zhongke Biological
Ningbo Rongan Biological Pharmaceutical
Guangzhou Nuocheng Biological